Vivo Capital VIII, LLC and Vivo Capital IX, LLC filed Amendment No. 6 to their Schedule 13D regarding Sinovac Biotech Ltd. (NASDAQ: SVA) on 11 July 2025. The filing updates share ownership and details an ongoing proxy and litigation battle over control of Sinovac's board. Ownership: Vivo Capital VIII reports 1,361,236 common shares (1.9%) ; Vivo Capital IX reports 4,541,764 common shares (6.3%), based on 71,860,702 shares outstanding, for a combined 8.2% economic interest. Both entities have shared voting and dispositive power over their respective holdings. Purpose of transaction: The amendment narrates events surrounding a Special Meeting called for 8 July 2025. Sinovac sought a court injunction to exclude Vivo and another investor from voting.